Across 17 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Garg Pushkal. Insider active across 1 company, notably ALNYLAM PHARMACEUTICALS, INC.. Cumulatively, 59 disclosures have been published. Breakdown: 0 buy · 40 sells. Total volume traded: €8.7m. Activity tracked since 3 August 2022. The latest transaction was disclosed on 13 February 2026 (Cession). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Garg Pushkal
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
349 shares@ US$252.500.7% of flowCommon StockSEC:0001735276-25-000009:1
25 of 59 declarations
About Garg Pushkal
Public sources indicate that Dr. Pushkal Garg works at Alnylam Pharmaceuticals. He joined Alnylam in 2014, was named Chief Medical Officer in January 2017, and became Executive Vice President in March 2019. In June 2025, Alnylam said he was promoted to Executive Vice President, Chief Research and Development Officer to oversee the combined R&D and Medical organization. The sources also say he previously held clinical development leadership roles at Bristol-Myers Squibb and Millennium Pharmaceuticals, and earlier was on the faculty at Harvard Medical School and Brigham and Women’s Hospital. Sources: https://www.sec.gov/Archives/edgar/data/1178670/000162828026023923/alny-20260406.htm